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Mutations in the NPHS2 gene, encoding podocin, are
responsible for familial autosomal recessive and sporadic
cases of steroid-resistant nephrotic syndrome. We have
successfully generated a mouse model in which the common
p.R138Q mutation found in nephrotic patients is expressed in
the kidney. Homozygous mice express the mutant protein,
which is mislocated to the cytoplasm, along with a portion of
the nephrin pool. These mice die within the first month of
life, but their survival depends on the genetic background.
Albuminuria manifests early and leads to progressive renal
insufficiency, characterized histologically by diffuse
mesangiolysis and mesangial sclerosis, endothelial lesions
along with podocyte abnormalities such as widespread foot
process effacement. Gene expression profiling revealed
marked differences between these and the podocin-null
mice, including significant perturbations of podocyte-
expressed genes such as Cd2ap, Vegfa and the transcription
factors Lmx1b and Zhx2. Upregulation of Serpine1 and Tgfb1
implicates these as potential mediators of disease
progression in these mice. This mouse model of nephrotic
syndrome may serve as a valuable tool in studies of in vivo
intracellular protein trafficking of podocyte proteins, as
well as testing therapeutic modalities aimed at correcting
the targeting of mutant proteins.
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Efforts over the past decade aimed at unravelling the genetic
basis of nephrotic syndrome have led to significant advances
in our understanding of the molecular basis of glomerular
function and the pathophysiological mechanisms leading to
proteinuric renal diseases. The NPHS2 gene, encoding the slit
diaphragm protein podocin, has been shown to be mutated
in familial forms of autosomal recessive steroid-resistant
nephrotic syndrome (SRNS),1 and in sporadic cases.2,3
Although early4 and adult-onset5 forms have been described,
SRNS most commonly manifests between 3 and 6 years of
age,1 rapidly progresses to end-stage renal disease, and does
not recur after transplantation. Mutations may involve both
N- and C-terminal intracytoplasmic regions of the protein,
and include both loss-of-function mutations as well as
missense changes.2 Indeed, the most commonly found
variant is the p.R138Q mutation, observed in 32% of all
affected alleles,2 and leads to a severe, early-onset form.4
Missense variants of podocin have been studied in cell culture
models and some, including the p.R138Q mutation, have
been shown to result in intracellular trafficking defects of
podocin, whereas some are able to maintain plasma
membrane targeting.6 Moreover, podocin has been shown
to function not only as a scaffold necessary for slit diaphragm
assembly via its interactions with CD2AP and nephrin,7 but
also in nephrin targeting to lipid rafts, where signal
transduction events occur.8 Missense podocin variants have
been shown to differ in their ability to affect nephrin
trafficking to lipid rafts and plasma membrane.9,10 More
recently, podocin has been shown to bind to cholesterol
regulating the activity of the transient receptor potential
channel 6.11
Murine models have proven to be invaluable tools in
elucidating the pathophysiological mechanisms leading to
renal disease. Indeed, we have previously inactivated the
murine Nphs2 gene and showed that these mice develop early,
and severe terminal renal disease, which differs phenotypi-
cally from disease seen in humans.12 We have, therefore,
developed a mouse model expressing the murine equivalent
of the missense variant p.R138Q to better understand the
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pathophysiological mechanisms involved in renal disease
caused by mutant forms of podocin. These mice developed
renal disease similar to that of the Nphs2-null model, due to
failure of the mutant protein to target properly in the
podocyte. We further demonstrated that survival can be
modulated by genetic background and that the renal disease
results in significant perturbations of gene expression in the
kidney.
RESULTS
Successful targeting leads to expression of the R140Q
podocin variant
The Nphs2 gene in mice encodes a protein with 385 amino
acids, two amino acids more than the human homolog. To
generate a mouse model bearing a mutant R140Q variant of
the podocin gene, corresponding to the p.R138Q mutation
found in humans, a 6.6-kb targeting construct was generated,
in which the c.505G4A, c.506A4G mutations were achieved
by site-directed mutagenesis of exon 3 of the Nphs2 gene, and
a floxed phosphoglycerate kinase–hygromycin cassette was
inserted into intron 3 for positive selection (Figure 1a).
Successful homologous recombination in 2/299 embryonic
stem cells was verified by Southern blot hybridization (Figure
S1) and two embryonic stem cell clones were expanded and
subsequently injected into C57BL/6 blastocysts. Germline
transmission of the mutant allele was achieved by mating of
480% chimeric mice from one clone and verified by
polymerase chain reaction (PCR) genotyping. Heterozygous
Nphs2R140Q/þ mice were crossed with Meu-Cre40 mice
constitutively expressing Cre recombinase,13 leading to
excision of the floxed hygromycin cassette. Finally, the Cre
allele was selected against by breeding heterozygotes with
wild-type mice.
In the mixed C57BL/6:129SvPas background, inheritance
of the mutant allele deviated from expected Mendelian
ratios, with 65/351 (18.5%) Nphs2R140Q/R140Q genotyped at
birth (w2¼ 8.11, 2 df, P¼ 0.0173), suggesting intrauterine or
perinatal mortality. Expression of the mutant Nphs2
transcript in Nphs2R140Q/þ and Nphs2R140Q/R140Q mice was
verified by sequencing the PCR products obtained after
reverse transcription of total RNA extracted from kidneys
(Figure 1b). By northern blot hybridization, no alternative
splice variants were seen in mutant Nphs2 mice, but Nphs2
transcriptional levels were higher than in wild-type mice
(Figure 1c). Real-time PCR confirmed significant upregula-
tion of the Nphs2 transcript at postnatal (P) day 4 and at P12,
although the latter did not achieve statistical significance
(Figure 1d). These results confirmed successful targeting of
the Nphs2 gene leading to expression of a podocin variant at
biologically relevant levels.
Mutant R140Q podocin is mislocalized, along with nephrin
Despite higher levels of Nphs2 mRNA in targeted mice,
western blotting revealed an overall decrease in the expres-
sion of podocin at the protein level as early as P1 (data not
shown), which was sustained at P12 (Figure 2). Previous
studies have revealed that the p.R138Q human podocin
variant, when overexpressed in cell culture models, fails to
localize to the plasma membrane and is retained in the
endoplasmic reticulum.6,10 We, therefore, investigated the
localization of podocin in homozygous Nphs2R140Q/140Q mice
by immunofluorescence. In wild-type mice, anti-podocin
antibodies labelled podocytes in a pattern consistent with
plasma membrane expression, in close juxtaposition to the
glomerular basement membrane marked by nidogen
(Figure 3a). In Nphs2R140Q/R140Q mice, however, podocin no
longer colocalized with nidogen, instead displayed an
intracellular pattern of expression with perinuclear staining,
indicating retention in the endoplasmic reticulum (Figure
3a). Additionally, in mutant mice, partial colocalization of
nephrin with mutant R140Q podocin suggests that the
intracellular trafficking defect of podocin leads to misloca-
lization of a fraction of the nephrin in podocytes (Figure 3b).
Mutant mice develop proteinuria and early, terminal renal
failure
Thereafter, cohorts of mutant R140Q mice were followed till
death or were killed at the designated time points.
Heterozygous Nphs2R140Q/þ mice followed to 1 year of age
did not demonstrate albuminuria and had no obvious renal
histological abnormalities (data not shown). Homozygous
mutant mice on the mixed genetic background died at a
median age of 4 days (range 1–40 days), with additional
mice likely dying either in utero or in the perinatal period
(Figure 4a). Previously, we had demonstrated a modifying
effect of genetic background on the survival of Nphs2-null
mice.12 We, therefore, backcrossed the mutant Nphs2R140Q
allele, enriching for 129S2/SvPas alleles, and the mice died at
a median age of 14 days, significantly later than mixed
background mice (Figure 4a). Furthermore, we identified
37/133 (27.8%) newborn Nphs2R140Q/R140Q mice on the 129-
enriched background, which suggests insignificant perinatal
mortality and is consistent with Mendelian inheritance.
Although appearing normal at birth, Nphs2R140Q/R140Q
newborn mice quickly developed albuminuria, which
progressed with age (Figure 4b). Biochemical measures of
renal function in 129 mutant mice demonstrated significant
elevations in plasma urea at both P4 and P12 (Figure 4c).
Similarly, plasma creatinine was elevated at P4 but not P12
(Figure 4d). This may potentially be accounted for by a trend
toward decrease in body weight at P12 in mutant podocin
(9.67±0.78 mg in controls vs 6.92±0.96 mg in mutants,
P¼ 0.06), which may reflect loss of muscle mass. These data
are consistent with early and significant impairment of renal
function in Nphs2R140Q/R140Q mice, and a potential role for
genetic modifiers in determining the length of survival.
Evolution of renal histological lesions in mutant mice
Thereafter, we characterized the evolution of renal histolo-
gical lesions in mutant mice and compared these with
littermate controls (Figures 5a and b). Despite the early onset
of albuminuria, light microscopy revealed no glomerular or
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tubular abnormalities during the first three days of life
(data not shown). At P4, surface hemorrhages were present in
the kidneys of Nphs2R140Q/R140Q mice corresponding to focal
areas of interstitial hemorrhages in the superficial cortex and
juxtamedullary areas (Figure 5c). Mesangial expansion and
focal areas of mesangiolysis were observed (Figure 5d), along
with focal dilatations of capillary lumina, but podocytes
appeared normal. Protein droplets were observed in proximal
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Figure 1 | Successful targeting of the murine Nphs2 allele resulting in expression of a mutant R140Q podocin. (a) Schematic
representations of the 6.6-kb targeting vector containing a modified exon 3 (light blue box) and a floxed phosphoglycerate kinase-hygromycin
cassette, the genomic structure of wild-type murine Nphs2 allele, and the allele resulting from homologous recombination. Exons are
represented by closed gray boxes. EcoRI restriction sites, the locations of internal and external probes, and the resulting digestion products are
noted. (b) Sequencing of PCR products, containing exon 3 of Nphs2, from Nphs2R140Q/þ and Nphs2R140Q/R140Q kidneys demonstrating the
mutant allele in the heterozygous and homozygous states. The PvuII restriction site is indicated by a black rectangle. The amino acid reading
frame is indicated above the chromatogram. (c) Northern blot of total RNA from kidneys of Nphs2þ /þ , Nphs2R140Q/þ , and Nphs2R140Q/R140Q mice
at P1 demonstrating increased expression of the 3.1-kb Nphs2 transcript in mutant mice. A 1.8-kb b-actin transcript was used as a loading
control. (d) Real-time PCR of Nphs2 confirmed an increase in Nphs2 mRNA levels in mutant mice (n¼ 6 at P4, n¼ 5 at P12) compared with
controls (n¼ 5 at each time point). * Denotes Po0.05 by t-test.
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tubules along with focal tubular dilatation (Figure 5e).
Arteries and arterioles were normal.
Mesangiolysis further worsened by P12, along with the
presence of mesangial sclerosis, reducing the patency of
capillary lumina (Figure 5f). Retraction of some sclerotic
glomeruli was observed, without adhesions to Bowman’s
capsule. Glomerular lesions were associated with tubular
alterations involving primarily the proximal tubules. These
tubules showed varying degrees of dilatation and the presence
of protein casts (Figure 5g). Mice killed at later time points (up
to 32 days) showed globally sclerotic and obsolescent glomeruli,
with severe and extensive tubulointerstitial lesions (Figure 5h).
Nphs2
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Figure 2 | Podocin levels are decreased in mutant mice. Western
blotting using protein lysates from wild-type and Nphs2R140Q/R140Q
mice at P12 showing a decrease in podocin expression in kidneys.
Proteins from the kidney of an Nphs2/ mouse were used as a
negative control and CBP80 as loading control.
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Figure 3 | Mutant R140Q podocin is mislocalized in the kidney, along with nephrin. (a) Confocal images showing podocin (in green)
plasma membrane staining in wild-type mice in close apposition to the glomerular basement membrane labelled with nidogen (in blue). In
contrast, mislocalization of podocin occurs in mutant mice at P4, with a perinuclear staining pattern (in relation to propidium iodide-stained
nuclei in red), suggesting retention of mutant podocin in the endoplasmic reticulum. Original magnification  630. (b) Double
immunolabelling with podocin (in green) and nephrin (in red) demonstrates partial colocalization in both wild-type and mutant mice at P4
suggesting nephrin pool mistargeting. Original magnification  630.
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Ultrastructural characterization of glomerular lesions
Electron microscopic studies of controls (Figure 6a and d)
and littermate mutant mice (Figure 6b, c, and e) at P10
revealed extensive changes affecting not only the podocytes
but also the mesangial and endothelial compartments.
Villous transformation of podocytes is evident along with
extensive vacuolization (Figure 6b) and foot process efface-
ment (Figure 6c). In rare areas where foot processes were
preserved, these were noted to be closely apposed without
any visible slit diaphragm (Figure 6e), in contrast with
control mice (Figure 6d). Widening of the sub-endothelial
space due to endothelial cell swelling was observed, leading to
uneven glomerular capillary wall thickening (Figure 6c).
Although endothelial fenestrae were focally preserved, they
were more frequently replaced by a continuous cytoplasmic
layer lining the periphery of the capillary loops. Irregular
edematous infiltration of the mesangial areas with disruption
of the mesangial strands and focal detachment of the
mesangial cells were present (Figure 6b and c).
Gene expression profile in mutant podocin mice
Finally, we used real-time PCR to investigate the effects of
mutant R140Q podocin on the gene expression profile in the
whole kidney at P4 and P12 (Table 1). We observed an
insignificant decrease in Nphs1 levels in Nphs2R140Q/R140Q
mice, whereas Cd2ap mRNA levels were upregulated. No
clearly significant changes were noted in either Trpc6 or Plce1
expression levels. Expression levels of transcription factors
implicated in glomerular function were assessed and revealed
transient, early upregulation of Wt1 and a late down-
regulation of Lmx1b. On the other hand, sustained elevations
in the transcriptional levels of the Tcf21 (encoding Pod1
transcription factor), Mafb (encoding Kreisler transcription
factor) and the Zhx1-3 genes were measured in Nphs2R140Q/R140Q
mice (Table 1). Given the prominent mesangial lesions,
including sclerosis, in these mice, the levels of expression of
the Vegfa, Serpine1 (encoding plasminogen activator inhi-
bitor-1), and Tgfb1 genes were quantified. In mutant mice,
although Vegfa levels were initially increased, they subse-
quently decreased by P12. On the contrary, sustained
upregulation of Serpine1 and Tgfb1 expression levels were
observed in Nphs2R140Q/R140Q mice.
The gene expression profile was compared with that of
constitutive podocin-knockout, mice. Despite similarities in
renal phenotypes, the levels of Nphs1, Trpc6, and Plce1 genes
were markedly downregulated in podocin-null mice at P12
(Table 1). Additionally, we found no increases in Mafb, Zhx2,
or Tgfb1 levels, which were instead unchanged or decreased.
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Figure 4 | Early mortality and renal insufficiency develop in mutant podocin mice. (a) Mortality in Nphs2R140Q/R140Q mice in the mixed
and 129-enriched genetic backgrounds. (b) Coomassie blue-stained gel of urines from wild-type and mutant mice showing presence of
albuminuria at P4, progressing to non-selective proteinuria by P12. (c) Early and sustained elevation in plasma urea in mutant mice at P4
and P12 (n¼ 5 at each time point) compared with controls (n¼ 4 at each time point). (d) Early increase in plasma creatinine levels in mutants
at P4 (n¼ 5) as compared with controls (n¼ 4). * Denotes Po0.05 by t-test.
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Moreover, the Zhx1 gene was downregulated at P12. On the
contrary, both Vegfa and Serpine1 were similarly perturbed
with loss of podocin.
DISCUSSION
Mutations in the NPHS2 gene account for 43% of familial
autosomal recessive and 10.5% of sporadic cases of steroid-
resistant nephrotic syndrome.2 Among these, missense
variants account for a significant proportion of pathogenic
mutations. We have previously found that the age of onset of
nephrotic syndrome in patients with NPHS2 missense
mutations correlates with the ability of podocin mutants,
during in vitro studies, to traffic correctly in the cell.6
Podocin mutants able to reach the plasma membrane are
associated with later onset than mutants retained in the
endoplasmic reticulum.6 The p.R138Q mutant represents the
most common mutation found in our cohort of patients, and
has been shown to be retained in the endoplasmic
reticulum.6,10 Furthermore, Huber et al.9 have shown that
this results in failure of nephrin to reach specialized lipid
raft microdomains, thereby abrogating the ability of podocin
to enhance nephrin-mediated activator protein-1 activity.
Immunohistochemical studies have, indeed, confirmed an
alteration in nephrin distribution in glomeruli obtained from
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Figure 5 | Evolution of renal histological lesions in mutant mice.
(a, b) Normal glomeruli and tubules seen in periodic acid–Schiff-
stained sections from Nphs2þ /þ mice at P12. Wild-type mice at P4
are identical and are not shown. (c) Interstitial hemorrhages are seen
in the cortical and juxtamedullary regions of mutant mice at P4.
Section stained with Masson’s trichrome-light green. (d) Periodic
acid–Schiff-stained section from a mutant mouse at P4 demonstrating
mesangial expansion, mesangiolysis, and capillary dilatation. (e) Focal
tubular dilation and vacuolization are present in mutant mice at P4.
(f) Progression of mesangiolysis and obstruction of glomerular
capillary loops seen in a periodic acid–Schiff-stained section of a
mutant mouse at P12. (g) Tubular dilation and protein casts are
present in mutant mice at P12. (h) Diffuse and global
glomerulosclerosis and severe tubulointerstitial lesions in a mutant
mouse at P32. Original magnification  1000 (a–g);  200 (h).
Figure 6 | Ultrastructural abnormalities in mutant podocin mice.
Electron microscopy performed on P10 kidneys from Nphs2þ /þ (a, d)
and Nphs2R140Q/R140Q (b, c, and e) mice. (b) Extensive changes seen in
the glomeruli of Nphs2R140Q/R140Q mice, including, podocyte
vacuolization, disorganization of the mesangial stalks with presence
of edematous areas, and reduced patency of capillary lumina.
Original magnification  1100. (c) Podocytes in Nphs2R140Q/R140Q mice
demonstrate foot process effacement and microvillous
transformation. Black arrows indicate an area where endothelial
fenestrations are preserved. Endothelial cell swelling is present
(designated by *). White arrowheads show areas of mesangial edema.
Original magnification  6000. (d) Podocyte foot processes in
wild-type mice are regularly spaced with slit diaphragm in between
(original magnification  7900), whereas (e) the foot processes are
partially effaced in Nphs2R140Q/R140Q and have no slit diaphragms
(original magnification  5300).
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renal biopsies of NPHS2 patients.14 Interestingly, a recent
study identified carriers of the p.R138Q mutation to be at
4.9-times greater risk of developing FSGS, suggesting that
mislocalization of podocin may have pathological conse-
quences even in the heterozygous state.15
We believed that an in vivo system in which mutant
podocin protein is expressed in mice would provide insight
into the fate of abnormal proteins arising from common
missense mutations. Furthermore, recent studies have shown
that mutant proteins retained in the endoplasmic reticulum
may be aided by pharmacological interventions to reach the
plasma membrane,16,17 thereby increasing the value of a
murine model. To this end, we generated a novel mouse
model in which the R140Q podocin mutant, the equivalent
of the p.R138Q mutation in humans, is expressed in the
kidney.
Successful targeting of the murine Nphs2 allele by
homologous recombination led to the expression of the
R140Q variant, confirmed at the mRNA and protein levels.
Interestingly, we found that although mRNA levels of
podocin are upregulated, the corresponding protein levels
are significantly lower. Immunohistochemical studies con-
firmed that mutant podocin is expressed in the cell, but is
mislocalized to cytoplasmic compartments. It is probable that
the R140Q variant is misfolded and consequently targeted for
degradation in proteasome.18 Additionally, our data demon-
strate that this triggers mistargeting of only part of the
nephrin pool in the cell, but suggest that nephrin trafficking
may also occur via podocin-independent mechanisms.
In effect, Nphs2R140Q/R140Q mice recapitulate the renal
phenotypes seen in mice with constitutive loss of podocin,12
suggesting that the R140Q mutation is a loss-of-function
allele. Similar to patients bearing the p.R138Q mutation,
these mice develop albuminuria early, associated with
widespread foot process effacement and progress to terminal
renal failure within the first month of life. However, as
opposed to NPHS2 patients in whom renal lesions range
from minimal change disease to focal and segmental
glomerulosclerosis,1 these mice develop renal lesions of
mesangiolysis progressing to diffuse mesangial sclerosis, and
ultrastructural evidence of endothelial lesions. Interestingly,
podocyte-specific inactivation of podocin in the mature
kidney leads to renal histological lesions of FSGS, reminiscent
of the human disease (Esquivel EL, Mollet G, Lavin TA et al.
(Abstract) J Am Soc Nephrol 2006; 17: 24A). These findings
suggest that during the process of glomerulogenesis, which
continues during the first two weeks of life in mice,
inactivation of podocin or podocyte injury or mediators
present in the nephrotic milieu may lead to significant
disturbance of podocyte–endothelial cell–mesangial cross talk.
Indeed, Eremina et al.19 have shown that mesangiolysis
occurs when crucial signals from the podocyte, mediated by
vascular endothelial growth factor-A and likely acting
through the endothelial cells, are disrupted during glomer-
ulogenesis. Technical difficulties limited our ability to obtain
a gene expression profile limited to the renal glomerulus.
However, results from profiling of whole kidneys revealed
that the vascular endothelial growth factor pathway is
perturbed, and may account for the development of
mesangial and endothelial lesions.
Taking these limitations into consideration, quantitative
PCR revealed a modest, early upregulation of Cd2ap
transcription, as seen in podocin-null mice12 and during in
vitro studies.20 However, levels of other podocyte-expressed
genes are not robustly altered, but we cannot exclude that
additional perturbation occurs at the post-transcriptional
level or in pathways involved in protein degradation. CD2AP
binds to podocin and may provide a crucial link to the actin
cytoskeleton,7 the remodelling of which is involved in
podocyte foot process effacement. It has previously been
Table 1 | Gene expression profile in Nphs2R140Q/R140Q mice compared with Nphs2/ mice
Nphs2R140Q/R140Q Nphs2/
Expression levels (vs control) Expression levels (vs control)
Gene Protein P4 P12 P5 P12
Nphs1 Nephrin 0.80±0.19 0.87±0.20 1.94±0.84 0.58±0.20*
Cd2ap CD2-associated protein 1.83±0.43* 1.52±0.19 1.38±0.17 1.05±0.15
Trpc6 Transient receptor potential channel 6 Undetectable 0.92±0.33 1.06±0.53 0.48±0.11y
Plce1 Phospholipase Ce-1 1.31±0.24 0.91±0.20 1.96±0.81 0.45±0.21*
Wt1 Wilms’ tumor homolog 1.43±0.43 1.01±0.38 1.09±0.21 0.79±0.20
Lmx1b Lmx1b transcription factor 1.09±0.38 0.64±0.37 0.93±0.22 0.72±0.28
Tcf21 Transcription factor 21 (Pod1) 1.37±0.36 1.47±0.30 0.78±0.21 0.81±0.27
Mafb v-maf oncogene family protein B (Kreisler transcription factor) 1.84±0.43 2.29±0.90* 1.05±0.33 0.83±0.29
Zhx1 Zinc fingers and homeoboxes 1 1.80±0.32 1.56±0.50 0.80±0.13 0.67±0.13*
Zhx2 Zinc fingers and homeoboxes 2 1.50±0.40 1.86±0.70* 1.14±0.24 0.77±0.31
Zhx3 Zinc fingers and homeoboxes 3 1.82±0.49 1.29±0.36 1.01±0.40 0.99±0.46
Vegfa Vascular endothelial growth factor-A 1.50±0.25 0.59±0.09 0.83±0.17 0.59±0.18y
Serpine1 Plasminogen activator inhibitor-1 5.43±1.98* 7.98±2.62* 4.26±0.77* 4.28±1.62y
Tgfb1 Transforming growth factor-b 1.44±0.26 2.07±0.60* 1.27±0.28 0.90±0.14
Real-time PCR from kidneys of mice at P4 and P12 showed dysregulation of multiple genes in mutant Nphs2R140Q/R140Q mice (n=6, n=5 at P4 and P12, respectively) compared
with wild-type mice (n=4 at each time point). Expression profiling was similarly performed in Nphs2-null mice at P5 and P12 (n=5 at each time point) and compared with
controls (n=4 at each time point). Values are mean±s.d. and reflect fold change vs controls using 18S rRNA as endogenous control, and calculated using the 2DDCt method.
*Po0.05; yPo0.01.
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shown that CD2AP and podocin are targets of the LMX1B
transcription factor.21 Our data, however, demonstrate a
trend toward subsequent downregulation of Lmx1b in the
course of renal disease evolution. One recent study has shown
that overexpression of the ZHX2 transcription factor in a cell
culture model leads to a downregulation of the LMX1B
gene.22 Curiously, the levels of the ZHX transcription factors
decreased during the evolution of proteinuric renal disease in
a rat model of nephrotic syndrome.22 In contrast, we found
that Zhx2 transcriptional levels, exclusively expressed in
podocytes in the kidney,22 were upregulated in our model.
Moreover, upregulation of the Kreisler transcription factor
was measured, but its downstream targets in the podocyte are
unclear. Additional work will be necessary to better under-
stand the complex interactions among these different genes
in the course of renal disease evolution.
Additionally, our data provide further evidence of
involvement of the plasminogen activator inhibitor-1 and
transforming growth factor-b pathways in glomerular
disease. Prior studies have demonstrated an involvement of
these growth factors in the pathogenesis of mesangiolysis23
and diffuse mesangial sclerosis.24 Moreover, these are known
mediators of the pathophysiological mechanisms involved in
chronic kidney disease progression.25,26 We likewise demon-
strated genetic modification of the survival of these mutant
mice, with 129-enriched mutant mice surviving longer. It will
be of interest in the future to examine whether differential
regulation of the plasminogen activator-inhibitor-1 and
transforming growth factor-b pathways may play a role in
phenotypic modification by genetic factors.
Finally, we demonstrated that despite similarities in the
renal phenotypes of R140Q mutant and Nphs2-null mice,
there are distinct differences in the expression profiles of
select genes in the glomerulus, particularly those involved in
structural integrity and transcriptional regulation. On the
other hand, genes involved in progression were similarly
perturbed. These discrepancies may reflect discrete pathways
perturbed in the presence of a mutant, misfolded protein
necessitating engagement of degradation pathways. Alterna-
tively, they may arise from differences in genetic background,
since the Nphs2-null mice examined were 129 congenics,
whereas the mutant mice were only 129-enriched.
MATERIALS AND METHODS
Generation of Nphs2R140Q/R140Q mice
A 6.6-fragment containing exons 3 and 4 was obtained after HindIII
digestion of genomic DNA and the 30 HindIII site was mutated to a
NotI site and inserted into the pBluescriptIIKS vector (Stratagene, La
Jolla, CA, USA). Site-directed mutagenesis (Quick-Change kit;
Stratagene) was used to introduce the c.505G4A, c.506A4G
mutations, which created a PvuII site in exon 3. A floxed
hygromycin cassette (phosphoglycerate kinase–hygromycin) was
inserted in reverse orientation into intron 3 via an SmaI site
generated by site-directed mutagenesis.
The targeting vector was electroporated into 129S2/SvPAS
embryonic stem cells and selected in hygromycin-containing
medium. Hygromycin-resistant embryonic stem cell clones were
screened by Southern blot hybridization using internal and external
probes (Figure S1). Two clones were expanded and injected into
C57BL/6 blastocysts. Mice with greater than 80% chimerism were
mated to obtain germline transmission. Tail biopsies were
performed and genotyping was carried out by PCR using primers
(50-CCACTTGTGTAGCGCCAA-30 and 50-TTGGGAGAAGAGGCA
CAG-30) flanking the hygromycin cassette and a protocol consisting
of denaturation at 94 1C for 5 min followed by 35 cycles of
denaturation at 94 1C for 1 min, annealing at 55 1C for 1 min and
extension at 72 1C for 1 min, and a final extension step at 72 1C for
7 min. These mice were mated with Meu-Cre 40 mice constitutively
expressing Cre recombinase,13 excising the floxed hygromycin
cassette. Heterozygous Nphs2R140Q/þ mice were mated with wild-
type mice to select out the Cre recombinase gene and intercrossed to
produce homozygous Nphs2R140Q/R140Q mice on a mixed B6-129
genetic background. The Nphs2R140Q allele was backcrossed onto the
129S2/SvPas genetic background for three generations, enriching
129 alleles to about 75% content.
Mice were maintained in a specific pathogen-free environment
and experiments were conducted in compliance with ethical
standards established by the French government and by the ethical
committees of Inserm, Paris and Hoˆpital Necker.
Genotyping
Tail genomic DNA was extracted using the Nucleospin Tissue kit
(Macherey-Nagel, Hoerdt, France) and PCR was performed using
primers flanking exon 3 (50-CGAGTGGCTTCTTGTCCT-30 and
50-GAGACGGAGATCAACCTTGT-30). The PCR protocol consisted
of an initial denaturation step at 94 1C for 5 min, followed by 35
cycles of denaturation at 94 1C for 1 min, annealing at 55 1C for
1 min, and extension at 72 1C for 1 min, and a final extension step at
72 1C for 7 min. PCR products were digested using PvuII enzyme
(NE Biolabs, Ipswich, MA, USA) and separated on a 2% agarose gel,
revealing a 184-bp wild-type allele, and 80 and 104-bp bands (not
resolved) in heterozygous and homozygous mutant mice (Figure S2).
RNA extraction and real-time PCR
Total RNA was extracted from the kidneys of control (n¼ 5) and
mutant (n¼ 6 at P4 and n¼ 5 at P12) mice killed at P4 and P12,
using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). Similarly,
controls and Nphs2-null mice were killed at P5 and P12 (n¼ 4 and
n¼ 5 of each genotype and time point) and kidney RNA was
extracted. Northern blot hybridization was performed using 32P-
labelled cDNA consisting of exons 1 to 8 of the mouse Nphs2 gene.
Reverse transcription with random primers was performed on
500 ng of total RNA using SuperscriptII reverse transcriptase
(Invitrogen). Real-time PCR was performed on a TaqMan ABI
Prism 7700 Sequence Detection System (Applied Biosystems, Foster
City, CA, USA) using Absolute QPCR mix (Thermo Fisher
Scientific, Waltham, MA, USA) and pre-designed Assays-on-
Demand primers and probes (Applied Biosystems). Assays were
performed in duplicates and water controls were run as negatives.
Relative quantification of gene expression was performed using the
2DDCt method and 18S rRNA as endogenous controls.
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Western blot
Kidneys from control and mutant mice at P1 (data not shown) and
P12 were removed and lysed in buffer containing 0.5% CHAPS,
20 mM Tris, pH 7.5, 500 mM NaCl, and protease inhibitors
(Complete Mini, Roche, Basel, Switzerland). A 20-mg weight of
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protein lysates was separated on a 12% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis denaturing gel and transferred to
nitrocellulose Transfer Membrane (Schleicher & Schuell, Dassel,
Germany). The membrane was blocked with 5% low-fat milk, 2%
bovine serum albumin in Tween–Tris-buffered saline (TTBS) and
incubated overnight at 4 1C with rabbit polyclonal anti-podocin
antibody (Sigma, St Louis, MO, USA) at 1:2000 dilution. After
several washes with 1TTBS, membranes were incubated for 1 h
with anti-rabbit IgG horseradish peroxidase-linked antibody
(Cell Signaling, Danvers, MA, USA) diluted 1:2000 in blocking
buffer. Signals were revealed using the ECL system (GE Healthcare,
Buckinghamshire, England). Blots were reprobed with anti-CBP80
antibodies (kindly provided by Elisa Izaurralde, EMBL Heidelberg)
diluted 1:1000, after stripping with Restore Western Blot Stripping
buffer (Pierce, Rockford, IL, USA).
Urine and blood analyses
Blood was collected in heparinized tubes when mice were killed.
Plasma was obtained after centrifugation at 5000 g for 10 min.
Plasma chemistries were performed using an Olympus AU-400
multiparametric analyzer (Hoˆpital Bichat, Paris, France). Urine was
collected by bladder puncture and 2 ml were analyzed on a 10%
sodium dodecyl sulfate-polyacrylamide gel electrophoresis gel,
followed by Coomassie blue staining.
Histological analysis
Kidneys were fixed in alcoholic Bouin for 2 h, dehydrated, and
embedded in paraffin. Four-micrometer-thick sections were stained
with Masson’s Trichrome-light green or periodic acid–Schiff and
examined under a Leitz Orthoplan microscope (Leica Microsystems
GmbH, Wetzlar, Germany). For electron microscopy, tissue samples
were processed as previously described,28 and samples from
littermate controls were systematically examined under identical
conditions.
Immunohistochemical studies
Immunofluorescence staining was performed as described.12 Acet-
one-fixed sections (6–7 mm) were simultaneously incubated with
rabbit anti-podocin28 (diluted 1:500) or guinea pig anti-nephrin
(diluted 1:50; Progen, Heidelberg, Germany) and rat anti-nidogen
(diluted 1:100; Millipore, Billerica, MA, USA) antibodies. After
rinsing, slides were incubated with appropriate secondary Alexa
Fluor-conjugated antibodies (Invitrogen). Nuclei were labelled using
0.75mg ml1 propidium iodide (Sigma). Slides were examined using
a Zeiss confocal microscope (Carl Zeiss, Jena, Germany).
Statistical analyses
Values are reported as mean±s.e.m. Statistical comparisons were
performed using either Student’s t-test or Mann–Whitney test as
appropriate. Po0.05 was considered significant.
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